BridgeBio Pharma (BBIO) EBITDA (2018 - 2026)
BridgeBio Pharma (BBIO) EBITDA from Sep 30, 2018 to Mar 31, 2026. The TTM BridgeBio Pharma (BBIO) EBITDA is -$520M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
BridgeBio Pharma (BBIO) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -24.90% |
| 3 Years TTM | +4.29% |
| 5 Years TTM | -0.76% |
| All Time TTM | +24.60% |
Annual EBITDA change of BridgeBio Pharma (BBIO)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$105M | -79.77% |
| 2025 | -$518M | -11.74% |
| 2024 | -$587M | -2.33% |
| 2023 | -$601M | +18.88% |
| 2022 | -$505M | -11.45% |
| 2021 | -$571M | +20.67% |
| 2020 | -$473M | +78.25% |
| 2019 | -$265M | +59.01% |
| 2018 | -$167M | +280.88% |
| 2017 | -$44M | N/A |
Comparison BridgeBio Pharma (BBIO) five years EBITDA CAGR with competitors
BridgeBio Pharma (BBIO) five years EBITDA CAGR is -0.76%.